Background: The ferroptosis inhibitory gene solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) inhibit ferroptosis in carcinoma cells. However, whether SLC7A11 and GPX4 serve as an oncogene in renal cell carcinoma (RCC) remains unclear. Methods: Immunohistochemistry (IHC) assays were performed to assess the expression of SLC7A11 and GPX4 in human RCC tissues. Clinical-pathological analysis was performed to explore the correlation between SLC7A11 and GPX4 expression. Kaplan-Meier survival analysis was performed to characterise the associations between protein expression and patient progressionfree survival (PFS). Results: The upregulation of SLC7A11 and GPX4 was detected by IHC in RCC tissues compared with that in normal renal tissues. Meanwhile, the expression level of SLC7A11 and GPX4 was correlated with tumour diameter and distant metastasis (P

中文翻译：

---

铁死亡相关蛋白SLC7A11和GPX4在肾细胞癌中的表达及预后意义

背景：铁死亡抑制基因溶质载体家族 7 成员 11 (SLC7A11) 和谷胱甘肽过氧化物酶 4 (GPX4) 抑制癌细胞中的铁死亡。然而，SLC7A11 和 GPX4 是否作为肾细胞癌 (RCC) 的癌基因尚不清楚。方法：采用免疫组织化学 (IHC) 检测评估人肾细胞癌组织中 SLC7A11 和 GPX4 的表达。通过临床病理分析探讨SLC7A11与GPX4表达之间的相关性。进行 Kaplan-Meier 生存分析来表征蛋白质表达与患者无进展生存 (PFS) 之间的关联。结果：与正常肾组织相比，IHC 检测到 RCC 组织中 SLC7A11 和 GPX4 表达上调。同时，SLC7A11和GPX4的表达水平与肿瘤直径和远处转移相关（P